EDMONTON, Jan. 3 /CNW/ - Isotechnika Inc. (TSX:ISA) announced today that the last patient enrolled in the Company’s Phase 2b kidney transplant trial has completed the six month trial.
EDMONTON, Jan. 3 /CNW/ - Isotechnika Inc. (TSX:ISA) announced today that the last patient enrolled in the Company’s Phase 2b kidney transplant trial has completed the six month trial.